Kuria Therapeutics, based in Little Rock, Arkansas, focuses on developing innovative therapeutics for ophthalmic and dermal conditions. Their lead program, KTX-1161, targets the corneal endothelium, aiming to treat and prevent diseases with high unmet medical need. By harnessing the power of Nrf2 biology, the company aims to activate the body's master regulator of cytoprotection, antioxidant response, and detoxification. Kuria Therapeutics is dedicated to developing a potent Nrf2 activator for multiple eye and skin conditions.